Blueshift Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Blueshift Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-513	Closed	-$246K	–	346
2023 Q1	$246K	Sell	513 -216	-30%	-$101K	0.1%	263
2022 Q4	$307K	Sell	729 -867	-54%	-$350K	0.14%	220
2022 Q3	$666K	Sell	1,596 -1,858	-54%	-$926K	0.14%	210
2022 Q2	$1.71M	Buy	3,454 +2,927	+555%	+$1.52M	0.28%	96
2022 Q1	$297K	Sell	527 -1,484	-74%	-$895K	0.03%	614
2021 Q4	$1.52M	Buy	+2,011	New	+$1.5M	0.13%	206
2021 Q3	–	Sell	-2,167	Closed	-$1.4M	–	1016
2021 Q2	$1.4M	Sell	2,167 -4,607	-68%	-$2.8M	0.08%	280
2021 Q1	$3.87M	Buy	+6,774	New	+$4.01M	0.4%	53
2020 Q4	–	Sell	-1,037	Closed	-$535K	–	698
2020 Q3	$535K	Buy	+1,037	New	+$525K	0.07%	332
2019 Q4	–	Sell	-1,775	Closed	-$591K	–	797
2019 Q3	$591K	Sell	1,775 -3,409	-66%	-$1.11M	0.09%	324
2019 Q2	$1.62M	Buy	5,184 +154	+3%	+$46.1K	0.21%	143
2019 Q1	$1.54M	Buy	5,030 +3,597	+251%	+$971K	0.22%	144
2018 Q4	$333K	Buy	+1,433	New	+$384K	0.06%	453

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Blueshift Asset Management's BIO Position: Q2 2023 in Review

Blueshift Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 513 shares — an estimated $246K sold.

Blueshift Asset Management first reported a position in BIO in Q4 2018 and held it in 13 quarters. The position peaked at $3.87M in Q1 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Blueshift Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
Blueshift Asset Management sold 513 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $246K.
Blueshift Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 13 quarters.
Blueshift Asset Management's Bio-Rad Laboratories Class A position peaked at $3.87M in Q1 2021.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Blueshift Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.